With an expiration date still more than a year away, here's what the latest details reveal.
The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.
The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...
An ADHD diagnosis means a person is prone to impulsivity and distractibility, which can manifest in the form of substance misuse, traffic accidents, criminality and even suicidal behavior. A recent ...
Treatment linked to reduced rates of first occurrence of suicidal behaviors, substance misuse, transport accidents, criminality. HealthDay News — Attention-deficit ...
23don MSN
Hyderabad-based pharmaceutical gets US nod for generic ADHD drug: Why this matters and what it means
ADHD is a neurodevelopmental condition that affects both children and adults. It is characterised by symptoms such as difficulty concentrating, impulsive behaviour and hyperactivity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results